Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALN-4285 in healthy volunteers
NCT07295717Phase 1Recruiting
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing ALN-4285 with Placebo (2 arms). Primary endpoint: Frequency of Adverse Events at 24 weeks. Started Dec 2025; status: recruiting.
02
Drugs
ALN-4285
Beyond the preview
Go deeper on NCT07295717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07295717.